Daicel (4202) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The cumulative results for Q3 of the fiscal year ending March 2026 showed lower revenue and lower profit, with deteriorating profitability in the core Materials Business and Engineering Plastics Business weighing on overall earnings. Revenue was ¥424.82B (前年比-1.8%, -¥7.72B), Operating Income was ¥32.44B (同-25.0%, -¥10.80B), Ordinary Income was ¥33.89B (同-24.3%, -¥10.90B), and Net Income was ¥36.48B (前年¥44.67B). The decline in profit significantly exceeded the decline in revenue, highlighting deterioration in the cost and expense structure as the core issue in these results.

Factors Affecting Performance

【Revenue】Revenue was ¥424.82B, down 1.8% year on year. The Safety Business secured higher revenue through increased inflator sales in China and India, but the Materials Business recorded lower revenue due to inventory adjustments by local customers for acetate tow and foreign exchange effects. Engineering Plastics also posted a largely flat decline in revenue due to factors including lower POM sales. Lower revenue from both businesses pushed down overall results.

【Profit and Loss】Operating Income was ¥32.44B, down 25.0% year on year, and the Operating Income Margin declined approximately 2.4pt from the previous year to 7.6%. Operating Income in the Materials Business decreased 45.2% due to moving-average price differences and increased costs associated with the conversion of Toyama Filter Tow into a wholly owned subsidiary. Engineering Plastics also posted a 25.6% decline in profit due to higher depreciation expenses and scheduled maintenance costs following the start-up of a new plant. In contrast, the Safety Business posted a 64.8% increase in profit, driven by cost reductions and foreign exchange effects. Ordinary Income was ¥33.89B (同24.3%減), representing a decline rate broadly in line with Operating Income. Profit Before Tax was ¥51.02B, ¥17.13B above Ordinary Income, primarily due to extraordinary income of ¥18.81B, including a gain on the sale of investment securities of ¥17.06B; this was a temporary factor. Of Net Income of ¥36.48B (consolidated), Net Income attributable to owners of the parent was ¥35.70B, with the extraordinary income effectively supporting net profit. On an Operating Income basis, which measures the earnings power of the core business, the results can be characterized as lower revenue and lower profit.

Segment Analysis

The Engineering Plastics Business had the largest revenue composition, with revenue of ¥185.9B, approximately 44% of total revenue, making it the core business. Operating Income in this business was ¥15.3B (前年比-25.6%), with increased depreciation expenses and scheduled maintenance costs following the start-up of a new plant serving as factors behind the decline.

The Materials Business recorded the highest Operating Income among segments at ¥10.5B, but posted a substantial 45.2% year-on-year decline and made the largest contribution to the overall decrease in profit. Factors included inventory adjustments for acetate tow, foreign exchange effects, and costs associated with the conversion of Toyama Filter Tow into a wholly owned subsidiary. Meanwhile, the Safety Business secured higher profit, with Operating Income of ¥5.0B (同+64.8%), supported by expanded inflator sales in China and India and cost reductions. Although small in scale, the Medical and Healthcare Business posted strong growth, with Operating Income of ¥0.6B (同+75.1%), while the Smart Business returned to profitability from a loss in the previous year. Across segments, deteriorating profit margins in Materials and Engineering Plastics pushed down overall results, while improvement in Safety partially offset the decline.

Key Financial Indicators

Profitability indicators were ROE of 9.1% and an Operating Income Margin of 7.6%. The gross margin was 25.9% and the SG&A ratio was 18.2%, with the Operating Income Margin declining from the previous year.

The Equity Ratio was 45.3%, while the current ratio was approximately 193.5% (current assets of ¥421.45B / current liabilities of ¥217.82B), indicating a sound level of short-term financial health. Construction in progress, which indicates capital expenditure trends, was ¥91.37B, accounting for approximately 24.9% of property, plant and equipment. Large-scale investments, including Engineering Plastics and the transition to cellulose-based manufacturing processes, are currently under way.

Cash Flow Analysis

This report does not include specific monetary data for Operating CF, Investing CF, or Financing CF, and therefore no calculations have been performed. As reference information, inventories of ¥184.40B and trade receivables of ¥116.66B have both increased from the previous year, making the expansion of working capital a point of concern from a cash flow perspective. Short-term borrowings increased 30.7% year on year, apparently reflecting increased working capital requirements associated with capital expenditures.

Quality of Earnings

Profit Before Tax was ¥51.02B, ¥17.13B above Ordinary Income of ¥33.89B. This difference was attributable to extraordinary income of ¥18.81B, primarily consisting of a ¥17.06B gain on the sale of investment securities, and was a temporary factor. Excluding extraordinary income, underlying Profit Before Tax would have been near the level of Ordinary Income, while the gain on the sale of investment securities accounted for approximately 48% of Net Income attributable to owners of the parent of ¥35.70B. Non-operating income of ¥6.01B represented only 1.4% of revenue, indicating that the scale of non-core income was small. Accordingly, the increase in Net Income for the period should be viewed not as an improvement in recurring earnings power, but as a temporary boost from asset sales.

Earnings Forecast and Guidance

Progress against the full-year forecasts (Revenue of ¥583.00B, Operating Income of ¥46.50B, and Ordinary Income of ¥47.50B) was 72.9% for Revenue, 69.8% for Operating Income, and 71.4% for Ordinary Income. Compared with standard progress of 75%, Revenue was 2.1pt below and Operating Income was 5.2pt below the benchmark, implying that the Operating Income Margin needs to recover to approximately 8.9% in Q4. The company has maintained its full-year forecasts and states that the impact of the CO plant trouble that occurred in January, approximately ¥1.0B, has already been factored in. The start-up of the new COC resin plant has been postponed to Q4 of the fiscal year ending March 2027, and the sales volume plan has been revised downward to -4% versus the previous fiscal year (previous forecast: +45%).

Shareholder Returns

The annual dividend forecast remains unchanged at ¥60.00 (interim ¥30.00, year-end ¥30.00). The Payout Ratio against forecast EPS of ¥192.75 is approximately 31.1%. The company has a policy of a Total Return Ratio of at least 40% and DOE of at least 4%, and is currently conducting a share repurchase of up to ¥15.0B (11.0M shares). Treasury shares have decreased year on year (book value: -¥9.82B). Dividends alone should be evaluated using the Payout Ratio, while share repurchases should be included when assessing the Total Return Ratio.

Catalysts

【Short Term】Progress in production adjustments and inventory reduction for acetate tow in the Materials Business during Q4, and the extent of recovery in profitability toward achieving the full-year Operating Income forecast.

【Long Term】The start-up of the new COC resin plant in Q4 of the fiscal year ending March 2027 and alignment between supply and demand, as well as the company’s ability to capture expanding demand for AI servers and 5G applications in Engineering Plastics.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The Operating Income Margin is slightly below the industry median, while the Net Profit Margin exceeds the median partly due to the contribution from extraordinary income.

Growth and Capital Efficiency

The Revenue Growth Rate is significantly below the industry median, confirming that the company is in a declining-revenue phase compared with peers that are generally experiencing revenue growth.

※Source: Compiled by the Company

Risk Factors

1. Deteriorating profitability in the core Engineering Plastics and Materials Businesses: Operating Income in Engineering Plastics decreased 25.6% due to higher depreciation expenses and scheduled maintenance costs following the start-up of a new plant, while Materials posted a 45.2% decline in profit due to inventory adjustments for acetate tow and foreign exchange effects. The two businesses together account for approximately 72% of revenue, creating a structure in which earnings fluctuations have a significant impact on overall performance.

2. Expansion of working capital: Inventories were ¥184.40B and trade receivables were ¥116.66B, both increasing from the previous year. The impact of delayed shipments due to inventory adjustments by local acetate tow customers is placing a burden on capital efficiency.

3. Risk of revisions to the investment plan: The start-up of the new COC resin plant has been postponed to Q4 of the fiscal year ending March 2027, and the sales volume plan has been revised downward. Construction in progress was ¥91.37B, accounting for approximately 24.9% of property, plant and equipment, and changes in the timing of investment recovery could affect future earnings plans.

Key Points from the Results

1. The Operating Income Margin declined approximately 2.4pt from the previous year to 7.6%, below the industry median of 8.6%. The primary causes of the profit decline were higher costs in the Materials and Engineering Plastics Businesses, making this an important indicator of changes in core earnings power.

2. Approximately 48% of Net Income attributable to owners of the parent of ¥35.70B was generated by gains on the sale of investment securities, a fact that needs to be distinguished from recurring profit growth.

3. The full-year Operating Income progress rate was 69.8%, below standard progress of 75%, indicating that a higher profit margin than the cumulative level will be required in Q4. This is an important point to verify in future earnings results.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,642–¥1,740 at ±1% for the Cost of Equity, and ¥1,685–¥1,698 at ±0.1 for ω.

Note:

• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).

（Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated values based solely on publicly disclosed data; these are not forecasts of the market share price or recommendations for any specific investment action, and do not predict or guarantee future share prices）

---

This report is an earnings analysis document automatically generated by AI through integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Daicel’s FY2026 Q3 results show weaker underlying operating performance, while reported profit was supported by substantial gains on the sale of investment securities. Cumulative Q3 revenue declined 1.8% year on year to ¥424.8bn. Operating income fell 25.0% to ¥32.4bn, materially underperforming the modest sales decline. The gross profit margin contracted to 25.9% from 28.0% in the prior-year period, a decline of approximately 215bp. The operating margin fell to 7.6% from 10.0%, a sharper 235bp contraction. SG&A expenses decreased 0.6% to ¥77.4bn, but this was insufficient to offset a 9.3% decline in gross profit. Ordinary income decreased 24.3% to ¥33.9bn. Profit attributable to owners of parent declined 18.9% to ¥35.7bn, less severe than the operating-income decline because pre-tax profit benefited from extraordinary items. In particular, the company booked a ¥17.1bn gain on sales of investment securities, which accounted for 47.8% of profit attributable to owners. This means the 8.4% reported net margin is not representative of underlying operating profitability. The annualized ROE of 11.9% remains within the 10-15% good range, but is flattered by the securities-sale gain and financial leverage. The balance sheet remains liquid, with a 193.5% current ratio and a 108.8% quick ratio. However, receivable days of 75, inventory days of 160, and a 177-day annualized cash conversion cycle point to substantial working-capital absorption in the manufacturing cycle. Construction in progress increased to ¥91.4bn, or 24.9% of PPE, indicating a sizable investment pipeline that must be completed on time and generate adequate returns. The FY2026 operating-income forecast of ¥46.5bn implies Q3 progress of 69.8%, below the standard 75% pace, while the fourth quarter would need to produce ¥14.1bn of operating income. The full-year dividend forecast of ¥60 per share implies a moderate 31.1% dividend payout ratio against forecast EPS of ¥192.75. Overall, the key near-term issue is whether margin recovery and execution of the investment program can offset weak operating momentum after stripping out non-recurring securities gains.

Profitability Analysis

The reported annualized ROE is 11.9%, decomposed into an 8.4% net profit margin, 0.641x annualized asset turnover, and 2.21x financial leverage. Financial leverage is the principal support for the return profile, as the operating margin of 7.6% is below the stated 8% threshold for a good manufacturing profitability level. The largest adverse year-on-year movement is margin compression: gross margin declined about 215bp and operating margin about 235bp. Revenue decreased only 1.8%, whereas operating income fell 25.0%, demonstrating negative operating leverage from the gross-profit shortfall. Gross profit decreased 9.3% to ¥109.8bn, while SG&A declined only 0.6% to ¥77.4bn; therefore, SG&A consumed a larger share of sales despite modest absolute cost control. Ordinary income margin was 8.0%, compared with the operating margin of 7.6%, as non-operating income of ¥6.0bn exceeded non-operating expenses of ¥4.6bn. Interest coverage was still solid at 13.85x, indicating that the current debt service burden is manageable. The extended DuPont interest-burden ratio of 1.573x is above 1.0 because profit before tax includes extraordinary gains, particularly investment-security disposals; it should not be interpreted as a recurring financing benefit. Profit before tax of ¥51.0bn exceeded ordinary income by ¥17.1bn, mainly reflecting ¥18.8bn of extraordinary income against ¥1.7bn of extraordinary loss. The ¥17.1bn securities-sale gain therefore materially boosts reported profitability but is non-recurring by nature. The effective tax rate was 28.5%, and the tax burden ratio was 0.700, broadly normal. The tax burden is not the cause of the year-on-year earnings decline; weaker gross profitability is the core driver. For a capital-intensive chemical manufacturer, annualized asset turnover of 0.641x reflects a relatively asset-heavy operating model, with PPE representing 41.5% of total assets. Sustained improvement in ROE will require recovery in operating margin and more productive utilization of the expanding fixed-asset base rather than further reliance on realized investment gains.

Growth Assessment

Revenue of ¥424.8bn was down 1.8% year on year, indicating that top-line conditions remain soft. The disproportionate 25.0% decline in operating income indicates that pricing, product mix, input-cost absorption, plant utilization, or a combination of these factors has been unfavorable, as evidenced by the gross-margin contraction. Gross profit fell ¥11.3bn year on year, compared with only a ¥0.5bn reduction in SG&A expenses. This cost structure produced negative operating leverage and limits the quality of the reported earnings outcome. The full-year revenue forecast is ¥583.0bn, and Q3 cumulative revenue progress is 72.9%, slightly below the standard 75% progress rate. Full-year operating-income forecast progress is 69.8%, 5.2 percentage points below the standard Q3 pace. Ordinary-income progress is 71.3%, also below the 75% seasonal benchmark. Profit attributable to owners has reached 71.4% of the ¥50.0bn forecast, but this apparent progress includes the large securities-sale gain. The implied fourth-quarter revenue requirement is ¥158.2bn, while the implied operating-income requirement is ¥14.1bn. This equates to a required Q4 operating margin of approximately 8.9%, above the 7.6% achieved cumulatively through Q3. Accordingly, delivery of guidance requires a meaningful sequential margin recovery. Construction in progress of ¥91.4bn suggests ongoing capacity, efficiency, or strategic investment, but its 24.9% share of PPE raises execution importance. In the chemical manufacturing context, revenue and margin recovery remain exposed to demand conditions, feedstock and energy costs, customer inventory adjustments, foreign-exchange movements, and competitive pricing. FX losses were ¥1.2bn during the period, equivalent to 3.7% of operating income, which is not the principal earnings driver but remains relevant given the company’s international asset base. The sustainable growth test for FY2026 is therefore not the reported net-income outcome, but whether operating income can recover sufficiently in Q4 without further dependence on asset disposals.

Financial Health

Liquidity is sound. Current assets of ¥421.4bn exceeded current liabilities of ¥217.8bn, producing working capital of ¥203.6bn and a current ratio of 193.5%. The quick ratio was 108.8%, showing that current obligations are covered even before relying on inventory liquidation. Cash and deposits were ¥75.8bn, and the reported cash-to-short-term-debt ratio was 1.62x. Total interest-bearing debt was ¥215.1bn, equivalent to a debt-to-equity ratio of 1.21x and debt-to-capital ratio of 35.0%. These measures are below the 2.0x D/E warning threshold and the 40% debt-to-capital investment-grade benchmark, respectively. Interest coverage of 13.85x provides a substantial earnings buffer against current interest costs. Short-term loans rose 30.7% year on year to ¥46.9bn, while long-term loans increased 21.8% to ¥168.2bn. Short-term debt represents 21.8% of interest-bearing debt, limiting refinancing concentration relative to the predominantly long-term debt structure. Current portions of long-term loans were ¥11.8bn and short-term bonds payable were ¥21.0bn, so near-term funding requirements should be monitored alongside the cash balance and working-capital cycle. There is no immediate maturity mismatch because current assets are nearly double current liabilities, but elevated inventories make the quality and convertibility of current assets important. Total equity increased ¥25.2bn year on year to ¥400.2bn, while the equity ratio eased to 43.5% from 44.2% as liabilities and asset investment grew more rapidly. Treasury stock decreased in absolute magnitude by ¥6.3bn, from negative ¥16.2bn to negative ¥9.8bn, a 39.2% change that increased equity relative to an unchanged capital-stock base. Goodwill was only ¥0.6bn, or effectively 0.0% of equity and total assets, leaving the balance sheet with negligible acquisition-premium or goodwill-impairment exposure. Intangible assets were also modest at 1.3% of total assets. Asset retirement obligations were ¥1.3bn, equivalent to approximately 0.3% of total liabilities, indicating a limited recorded environmental-restoration liability relative to the liability base.

Notable B/S Changes

Short-term loans: +¥11.0bn (+30.7%) to ¥46.9bn - increased reliance on short-term borrowing; liquidity remains adequate but near-term funding should be monitored alongside the long cash conversion cycle. Long-term loans: +¥30.1bn (+21.8%) to ¥168.2bn - debt-funded investment or funding needs increased, although D/E of 1.21x and debt/capital of 35.0% remain manageable. Construction in progress: +¥25.2bn (+38.1%) to ¥91.4bn - large investment pipeline; CIP now represents 24.9% of PPE, creating completion, cost-overrun, and return-on-investment risk. Treasury stock: improved by ¥6.3bn (+39.2%) from negative ¥16.2bn to negative ¥9.8bn - reduced treasury-share deduction supports reported equity.

Cash Flow Quality

Working-capital efficiency is the central earnings-quality issue indicated by the available operating-balance data. Annualized receivable days were 75 days, above both the 60-day warning threshold and the 45-day efficient-manufacturing benchmark. The root cause is a receivables balance of ¥116.7bn relative to annualized revenue; slower collection or a more credit-intensive sales mix extends the conversion of accounting revenue into cash. For a chemical manufacturer, extended customer payment terms can occur in industrial supply chains, but 75 days remains elevated versus the stated benchmark. The impact is greater cash tied up in customer balances and increased sensitivity to customer-credit conditions. Annualized inventory days were 160 days, well above the 90-day warning threshold and the 60-day manufacturing efficiency benchmark. The root cause is an inventory balance of ¥184.4bn relative to annualized cost of sales. This level may reflect long production cycles, safety stocks, raw-material procurement requirements, or slower inventory turnover, but it creates heightened exposure to demand shortfalls, price declines, and obsolescence. The 160-day inventory metric is particularly material because inventories account for 20.9% of total assets and 43.8% of current assets. The annualized cash conversion cycle was 177 days, exceeding the 120-day warning threshold. The implied payable period is approximately 58 days, which provides normal supplier-credit support, but it is insufficient to offset the combination of slow receivables and very high inventories. The long cycle means capital remains committed for an extended period before conversion to cash, raising the importance of inventory discipline and collection management. Construction in progress was ¥91.4bn, representing 24.9% of PPE and exceeding the 20% high-CIP alert threshold. The root cause is a large unfinished capital-investment program rather than a mature fully operational asset base. This can be consistent with expansion or modernization in a capital-intensive chemical operation, but the impact is execution risk: delayed commissioning, cost overruns, or weak demand could defer the expected return on invested capital. The recorded balance-sheet indicators therefore call for close monitoring of receivables, inventory normalization, CIP commissioning, and the ability of operating earnings to support the enlarged asset base.

Dividend Sustainability

The company has paid an interim Q2 dividend of ¥30 per share and forecasts a full-year dividend of ¥60 per share. Against forecast FY2026 EPS of ¥192.75, the forecast dividend payout ratio is approximately 31.1%. This is comfortably below the 60% sustainability benchmark and leaves a substantial accounting earnings retention buffer. The provided interim payout calculation was 22.4%, based on the ¥30 per share Q2 dividend and cumulative net income. The full-year dividend commitment appears proportionate to the earnings forecast rather than aggressive. Retained earnings were ¥259.8bn, providing a sizeable equity buffer. The company’s liquidity position is also supportive, with ¥75.8bn of cash and deposits, a 193.5% current ratio, and 13.85x interest coverage. However, the quality of reported Q3 earnings is reduced by the ¥17.1bn gain on sale of investment securities. Dividend sustainability should therefore be assessed primarily against recurring operating profit recovery and the full-year EPS forecast, rather than cumulative net income alone. The elevated 177-day annualized cash conversion cycle and ¥91.4bn construction-in-progress balance increase the importance of maintaining disciplined capital allocation. There is no evidence in the supplied period data of a dividend level that would exceed forecast earnings capacity. The principal policy risk would arise if margin recovery falls short of the Q4 level required to achieve the full-year forecast.

Risk Assessment

Business risks include Margin-recovery risk: revenue fell 1.8% but operating income declined 25.0%, and the operating margin compressed 235bp to 7.6%. This indicates high sensitivity of earnings to sales mix, pricing, input costs, and plant utilization., Chemical-manufacturing demand and cost risk: industrial demand cycles, feedstock and energy-price volatility, customer destocking, foreign-exchange movements, and competitive pricing can materially affect gross margin., Inventory risk: annualized DIO of 160 days is above the 90-day warning level. The ¥184.4bn inventory balance exposes the company to inventory valuation, demand, and working-capital risks., Collection-cycle risk: annualized DSO of 75 days exceeds the 60-day warning threshold, increasing exposure to delayed customer collections and tying up funds in receivables., Capital-project execution risk: construction in progress of ¥91.4bn, equal to 24.9% of PPE, raises the risk of delayed commissioning, investment overruns, or returns below the cost of capital..

Financial risks include Debt increased, with short-term loans up 30.7% to ¥46.9bn and long-term loans up 21.8% to ¥168.2bn. Leverage remains manageable at 1.21x D/E and 35.0% debt/capital, but further debt-funded investment would reduce balance-sheet flexibility., The 177-day annualized cash conversion cycle is above the 120-day warning level. This raises the funding requirement associated with operations even though current liquidity ratios remain healthy., Reported pre-tax income was materially supported by a ¥17.1bn gain on sales of investment securities. Repetition risk is high because securities disposals are not a dependable recurring earnings source., FX losses of ¥1.2bn were equivalent to 3.7% of operating income, indicating a measurable, though not dominant, earnings sensitivity to currency movements..

Key concerns include Highest priority: underlying profitability weakened significantly, with operating income down 25.0% and the gross margin down approximately 215bp., Highest priority: FY2026 operating-income forecast progress is 69.8% at Q3, below the 75% standard pace; the company needs an approximately 8.9% Q4 operating margin to meet guidance., High priority: the combination of DSO of 75 days, DIO of 160 days, and a 177-day cash conversion cycle indicates inefficient working-capital deployment., High priority: the securities-sale gain represented 47.8% of profit attributable to owners, making reported net-income performance less indicative of recurring profitability., Medium priority: high construction in progress should be monitored for completion timing and returns, particularly while operating profitability is under pressure..

Investment Implications

Key takeaways include Cumulative Q3 revenue was broadly stable, but gross-profit and operating-margin compression drove a 25.0% decline in operating income., Reported profit attributable to owners of ¥35.7bn was supported by a ¥17.1bn gain on sales of investment securities, reducing the comparability of net income with recurring operations., The annualized ROE of 11.9% is respectable, but it is supported by 2.21x financial leverage and non-recurring gains rather than an 8%-plus operating margin., Liquidity and debt-service capacity are solid, with a 193.5% current ratio, 108.8% quick ratio, 35.0% debt/capital, and 13.85x interest coverage., Working-capital intensity and a high level of construction in progress are the main balance-sheet issues to monitor., The forecast ¥60 per share dividend implies a moderate 31.1% payout ratio based on forecast EPS..

Metrics to watch include Quarterly gross margin and operating margin, particularly whether the company can achieve the approximately 8.9% implied Q4 operating margin required for FY guidance., Operating-income progress relative to the ¥46.5bn full-year forecast., Receivable days, inventory days, and the annualized cash conversion cycle., Inventory balance and potential normalization from the ¥184.4bn Q3 level., Construction-in-progress completion, spending discipline, and conversion of the ¥91.4bn balance into productive operating assets., Net debt and the evolution of short-term and long-term loan balances., The extent of future securities sales and the contribution of non-recurring gains to pre-tax profit..

Regarding relative positioning, Daicel combines a sound liquidity profile, manageable leverage, and negligible goodwill exposure with below-target operating profitability and unusually heavy working-capital intensity. Relative financial resilience is stronger than the underlying Q3 margin trend, while earnings comparability is weakened by a large realized securities gain.